このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Opthea 将来の成長

Future 基準チェック /56

Optheaは、59.6%と62.9%でそれぞれ年率59.6%で利益と収益が成長すると予測される一方、EPSはgrowで59.4%年率。

主要情報

59.6%

収益成長率

59.4%

EPS成長率

Biotechs 収益成長	15.9%
収益成長率	62.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	17 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

CHIA:OPT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	105	-32	72	72	7
6/30/2025	12	-148	-139	-130	7
6/30/2024	1	-183	-169	-163	7
12/31/2023	0	-162	-121	-121	N/A
9/30/2023	0	-152	-121	-121	N/A
6/30/2023	0	-143	-121	-121	N/A
3/31/2023	0	-137	-116	-116	N/A
12/31/2022	0	-132	-112	-112	N/A
9/30/2022	0	-113	-92	-92	N/A
6/30/2022	0	-93	-71	-71	N/A
3/31/2022	0	-75	-64	-64	N/A
12/31/2021	0	-57	-56	-56	N/A
9/30/2021	0	-51	-51	-51	N/A
6/30/2021	0	-45	-46	-46	N/A
3/31/2021	0	-39	-36	-36	N/A
12/31/2020	0	-31	-27	-27	N/A
9/30/2020	0	-21	-16	-16	N/A
6/30/2020	0	-11	-6	-6	N/A
3/31/2020	0	-10	-7	-7	N/A
12/31/2019	0	-12	-10	-10	N/A
9/30/2019	0	-13	-13	-13	N/A
6/30/2019	0	-15	-17	-17	N/A
3/31/2019	0	-13	-14	-14	N/A
12/31/2018	0	-12	-11	-11	N/A
9/30/2018	0	-12	-13	-13	N/A
6/30/2018	0	-13	-15	-15	N/A
3/31/2018	0	-12	-13	-13	N/A
12/31/2017	0	-12	-12	-11	N/A
9/30/2017	0	-8	N/A	-8	N/A
6/30/2017	0	-5	N/A	-5	N/A
3/31/2017	0	-5	N/A	-4	N/A
12/31/2016	0	-5	N/A	-3	N/A
9/30/2016	0	-5	N/A	-3	N/A
6/30/2016	0	-5	N/A	-3	N/A
3/31/2016	0	-4	N/A	-2	N/A
12/31/2015	0	-3	N/A	-1	N/A
9/30/2015	0	-3	N/A	-2	N/A
6/30/2015	0	-4	N/A	-4	N/A
3/31/2015	1	-4	N/A	-4	N/A
12/31/2014	1	-4	N/A	-4	N/A
9/30/2014	1	-4	N/A	-4	N/A
6/30/2014	1	-4	N/A	-4	N/A
3/31/2014	1	-3	N/A	-4	N/A
12/31/2013	1	-2	N/A	-4	N/A
9/30/2013	1	-3	N/A	-5	N/A
6/30/2013	1	-4	N/A	-5	N/A

アナリストによる今後の成長予測

収入対貯蓄率: OPTは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.3% ) よりも高い成長率であると考えられます。

収益対市場: OPT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: OPT今後 3 年以内に収益を上げることが予想されます。

収益対市場: OPTの収益 ( 62.9% ) Australian市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: OPTの収益 ( 62.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: OPTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Opthea 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Shareholder dilution

Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD

New major risk - Financial position

New minor risk - Profitability

Less than half of directors are independent

Opthea Limited Announces Board Changes

Founder recently sold AU$2.2m worth of stock

Opthea Appoints Arshad M. Khanani as Chief Medical Advisor

Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Strengthens Team with Key Clinical and Regulatory Hires

Opthea Limited Announces Executive Changes

Opthea Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Full year 2023 earnings released: US$0.32 loss per share (vs US$0.26 loss in FY 2022)

Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

Opthea Limited Announces Executive Changes

Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board

First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022)

Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology

High number of new directors

Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer

Opthea Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: US$0.26 loss per share (vs US$0.14 loss in FY 2021)

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

Opthea Limited, Annual General Meeting, Sep 26, 2022

Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

High number of new directors

Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022

High number of new directors

Opthea Limited Announces Board Appointments

Opthea Limited Appoints Joel Naor, as Chief Medical Officer

Opthea Limited Announces Data for OPT-302 in Patients with PVC

Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020)

Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

High number of new directors

Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration

Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302

Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020)

New 90-day low: AU$1.78

New 90-day low: AU$1.81

New 90-day low: AU$2.11

New 90-day low: AU$2.30

Opthea Limited' ADR Deleted from Other OTC

Opthea Limited Appoints Dr. Jeremy Levin as Director

Geoffrey Kempler Retires as A Director of Opthea Limited

New 90-day high: AU$3.03

Opthea Limited Announces Board Changes

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

New 90-day high: AU$2.94

Opthea Limited(ASX:OPT) dropped from S&P/ASX Emerging Companies Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘